Reemergence of epidemic Vibrio cholerae O139, Bangladesh.

During March and April 2002, a resurgence of Vibrio cholerae O139 occurred in Dhaka and adjoining areas of Bangladesh with an estimated 30,000 cases of cholera. Patients infected with O139 strains were much older than those infected with O1 strains (p<0.001). The reemerged O139 strains belong to a single ribotype corresponding to one of two ribotypes that caused the initial O139 outbreak in 1993. Unlike the strains of 1993, the recent strains are susceptible to trimethoprim, sulphamethoxazole, and streptomycin but resistant to nalidixic acid. The new O139 strains carry a copy of the Calcutta type CT[X.sup.Calc] prophage in addition to the CT[X.sup.ET] prophage carried by the previous strains. Thus, the O139 strains continue to evolve, and the adult population continues to be more susceptible to O139 cholera, which suggests a lack of adequate immunity against this serogroup. These findings emphasize the need for continuous monitoring of the new epidemic strains.

**********

Vibrio cholerae O139 Bengal first emerged during 1992 and 1993 and caused large epidemics of cholera in Bangladesh, India, and neighboring countries (1-3). This new strain initially displaced the existing V. cholerae O1 strains. During 1994 to the middle of 1995, in most northern and central areas of Bangladesh, the O139 vibrios were replaced by a new clone of V. cholerae O1 of the El Tor biotype, whereas in the southern coastal regions the O139 vibrios continued to exist (4-6). During late 1995 and 1996, cases of cholera attributable to both V cholerae O1 and O139 were again detected in various regions of Bangladesh. Since 1996, cholera in Bangladesh has been caused mostly by V cholerae O1 of the El Tor biotype; only a few cases have been attributable to O139 serogroup strains. The epidemiology of cholera in Bangladesh changed again recently, and a large outbreak of cholera caused predominantly by V. cholerae O139 occurred in the capital city Dhaka and adjoining areas.

From early March to the end of April 2002, approximately 2,350 cholera patients associated with V cholerae O139 were admitted to the Dhaka Hospital of the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). A preliminary estimate showed that >30,000 cases of cholera occurred in Dhaka and the adjoining areas during this outbreak (A.S.G. Faruque, unpub. data). Spice the initial emergence of V. cholerae O139 in 1992, we have monitored cholera outbreaks caused by this serogroup in Bangladesh and neighboring regions and have conducted several studies to characterize O139 strains. These studies indicate that strains of the O139 serogroup are undergoing rapid genetic changes, resulting in the origination of new clones; at least seven different ribotypes of O139 vibrios have been documented (6-8). Furthermore, O139 vibrios may have originated from more than one progenitor strain (8). The transient disappearance and reemergence of V cholerae O139 in Bangladesh have raised questions regarding the origin of the reemerged O139 vibrios. In this study, we examined the current epidemiology of cholera in Bangladesh and analyzed V cholerae O139 isolated from the recent outbreak to investigate the origin of the recent epidemic strains as well as to characterize possible genetic changes in O139 vibrios that might have contributed to the recent resurgence of V. cholerae O139.

Materials and Methods

Clinical Surveillance

ICDDR,B maintains a 2% surveillance system at its Dhaka Hospital, in which data from every 50th patient treated at the hospital is collected; these data include clinical information and biologic specimens. We used these data to extrapolate the overall numbers of patients with cholera; specimens from these patients were used in the bacteriologic studies described.

V. cholerae Strains

A total of 63 V. cholerae O139 isolates obtained from the recent cholera epidemic were analyzed. Seven strains of O139 vibrios isolated in India between 1992 and 1996, 17 strains of V. cholerae O139 isolated in Bangladesh between 1993 and 1997, and 2 strains isolated in Thailand in 1998 were also included in the study for comparison with the recent epidemic strains. Strains of the recent epidemic were isolated from stools of cholera patients who attended the treatment center of ICDDR,B located in Dhaka during March and April 2002. Stool samples were processed in the laboratory within 2 h of collection for the isolation of V. cholerae. Stools were initially streaked on thiosulphate-citrate-bile-sucrose (Becton, Dickinson and Co., Sparks, MD) agar plates for selection and presumptive identification of V. cholerae. All strains were subsequently examined by biochemical and serologic tests using standard methods (9). Strains were stored in sealed deep nutrient agar at room temperature until used for this study. Details of the strains are shown in Table.

Polymerase Chain Reaction (PCR) Assays

Presence of tcpA genes specific for the classical and El Tor biotypes was determined by using a multiplex PCR assay, as described previously (10). PCR assays for the tcpI and acfB genes have been described previously (6). Presence of classical, El Tor, and Calcutta type rstR genes of CTX phage were also determined with PCR by using specific primers derived from the published sequence of the respective genes. Three different forward primers for rst[R.sup.class], rst[R.sup.ET], and rst[R.sup.Calc] with sequences 5'-CTTCTCATCAGCAAAGCCTCCATC, 5'-GCACCATGATTTAAGATGCTC, and 5'-CTGTAAATCTCTTCAATCCTAGG respectively, were used with a common reverse primer (5'-TCGAGTTGTAATTCATCAAGAGTG) to amplify the respective rstR genes. Presence of the rstC gene was also determined by a PCR assay described previously (11). All primers were synthesized commercially by Oswel DNA Service (University of Edinburgh, Edinburgh, UK). The expected sizes of the amplicons were ascertained by electrophoresis in agarose gels, and the identity of each PCR product was further verified by Southern blot hybridization.

Probes and Hybridization

The gene probes used in this study included a 0.5 kb EcoRI fragment of pCVD27 (12) containing part of the ctxA gene and a 2.1 kb SphI-XbaI fragment of pCTX-Km containing the entire zot and ace genes and part of orfU (13). The toxR gene probe was a 2.4-kb BamHI fragment of pVM7 (14). The rst[R.sup.ET] probe was a SacI-XbaI fragment of pHK1 (15). The rRNA gene probe was a 7.5-kh BamHI fragment of the Escherichia coli rRNA clone pKK3535 described previously (16). The O139-specific DNA probe 2R3 was a 1.3-kb EcoRI fragment of pCRII-A3 (17, 18), and the SXT probe was a NotI fragment of pSXTI (19). PCR-generated amplicons of the rstR genes of classical, El Tor, Or Calcutta type CTX prophage were also used as probes whenever appropriate.

For preparation of Southern blots, total cellular DNA was isolated from overnight cultures as described previously (20). Five-microgram aliquots of the DNA were digested with appropriate restriction enzymes (Bethesda Research Laboratories, Gaithersburg, MD), electrophoresed in 0.8% agarose gels, blotted onto nylon membranes (Hybond, Amersham Biosciences, Uppsala, Sweden), and processed by using standard methods (21,22). The probes were labeled by random priming (23) using a DNA labeling kit (Bethesda Research Laboratories) and [alpha]-[sup.32]P-deoxycytidine triphosphate (3,000 Ci/mmol, Amersham Biosciences). Southern blots were hybridized with the labeled probes at 68[degrees]C and washed under stringent conditions as described previously (6,8). Autoradiographs were developed from the hybridized filters with Kodak X-Omat AR x-ray film (Eastman Kodak Co., Rochester, NY) at -70[degrees]C.

Antimicrobial Resistance

All V. cholerae isolates were tested for resistance to antimicrobial drugs by using the method of Bauer et al. (24) with standard antibiotic disks (Oxoid Ltd., Basingstoke, Hampshire, UK) at the following antibiotic concentrations (mg/disc): ampicillin, 10; chloramphenicol, 30; streptomycin, 10; tetracycline, 30; trimethoprim and sulfamethoxazole, 1.25 and 23.75, respectively; kanamycin, 30; gentamicin 10; ciprofoxcin 5; norfloxacin 10, and nalidixic acid, 30.

Results

Clinical Surveillance

We noted a marked increase in cholera cases associated with V. cholerae O139 front March to May 2002 (Figure 1). The highest number of cholera patients admitted to the hospital was in March; 69.8% of these cases were attributed to V. cholerae O139, compared to 30.2% of cases caused by the El Tor biotype of V. cholerae O1. Cholera attributable to V. cholerae O139 occurred with similar frequencies in men and women, similar to those infected with O1 strains. From January 2001 to June 2002, a total of 91 (32%) of 282 of case-patients infected with O1 cholera were <5 years of age, but 15 (15%) of 115 of those infected with O139 were <5 years of age (p<0.001). During the same period, 48% of those infected with V. cholerae O1 were >15 years of age, while 76% of those infected with O139 were >15 years of age (p<0.001).

[FIGURE 1 OMITTED]

Genetic Analysis of V. cholerae Strains

The rRNA gene restriction patterns using Bg/I consisted of 10 to 14 bands between 11 kb and 1.6 kb in size (Figure 2). The 89 analyzed strains belonged to four different ribotypes (B-I to B-IV). All 63 recently isolated O139 strains produced identical restriction patterns of their rRNA genes and belonged to ribotype B-II. Analysis of the rstR gene showed that O139 strains isolated from 1992 to 1998 carried El Tor type CT[X.sup.ET] prophage, whereas the recent epidemic strains carry the Calcutta type CT[X.sup.Calc] prophage in addition to the CT[X.sup.ET] prophage (Figure 3). All strains were positive for fcpA, tcpI, acfB, toxT, ctxA, zot, and ToxR genes, as well as for the O139-specific genomic DNA in DNA probe or PCR assays.

[FIGURE 2 OMITTED]

Antibiogram

All strains isolated from the recent epidemic were resistant to nalidixic acid and were susceptible to ampicillin, tetracycline, gentamicin, chloramphenicol, ciprofloxacin, norfloxacin, streptomycin, trimethoprim, and sulfamethoxazole. In these strains, the SXT element, which encodes resistance to streptomycin, sulfamethoxazole, and trimethoprim, carried a deletion of an approximately 3.6-kb region.

Discussion

Generally, a seasonality exists in the cholera cases seen at the ICDDR,B hospital, with increased numbers expected before and after the rainy season. Thus, the increase in total number of cases seen during March and April was not unusual (Figure 1). However, the increase in patient numbers during these months of 2002 was associated with a marked increase in cases associated with V. cholerae O139, and the numbers of cases infected with serogroup O139 outnumbered those with serogroup O1. The ages of patients infected with O139 strains were significantly higher than those infected with O1 strains (p<0.001). Since the onset of O139 cholera in 1992, this organism has tended to infect patients older than those with O1 cholera (1). The more advanced age of this group was explained by a lack of immunity to this new serogroup in adults who were likely partially immune to the O1 serogroup. Thus, alter nearly 10 years of endemicity in Bangladesh, V cholerae O139 continues to cause more cases of cholera in older adults.

Ribotype Analysis

The emergence of the O139 serogroup has provided a unique opportunity to witness the epidemiologic changes associated with the displacement of an existing serogroup by a new emerging one and thus provides new insights into the epidemiology of the disease. All 63 recently isolated O139 strains produced the identical restriction pattern of their rRNA genes. This restriction pattern has been previously designated as ribotype pattern B-II (6-8) and was first detected among epidemic V. cholerae O139 strains that emerged in 1992 and 1993. Cholera epidemics during 1992 to 1993 in India and Bangladesh that were associated with the first appearance of V cholerae O139 were caused by strains belonging to two different ribotypes, designated as B-I and B-II. Since then, several new ribotypes of O139 vibrios have been detected which were associated with localized outbreaks during 1995 to 1996 or sporadic cases (8). The results suggest that strains of the recent epidemic were clonal and were derived from one of the initial clones of V. cholerae O139. We therefore investigated possible genetic changes sustained by this strain during the nearly 9 years since major epidemics were caused by strains of this ribotype.

Analysis of CTX Prophage

In V cholerae, the genes encoding cholera toxin (ctxAB) are part of the CTX prophage (25). A typical CTXF genome has two regions: core and the RS2. The 4.5-kb core region comprises several open reading frames including ctxAB, zot, ace, orfU, and encodes CT as well as the functions that are required for the virion morphogenesis; by contrast, the 2.5-kb RS2 region encodes the regulation, replication, and integration functions of the CTXF genome (26). Previous studies have described the existence of at least three widely diverse repressor genes (rstR genes) carried by different CTX phages (i.e., [CTX.sup.ET]F, [CTX.sup.class]F, and [CTX.sup.Calc]F) (27,28). This diversity of rstR constitutes the molecular basis for heteroimmunity among CTX phages, which are otherwise genetically similar. We examined the CTX prophage in the recent and previously isolated O139 strains with specific probes. Analysis of the rstR gene carried by the recent epidemic strains showed that, unlike the O139 strains of 1993, which carried multiple copies of an El Tor type [CTX.sub.ET] prophage, the new O139 strains carry at least one copy of the Calcutta type [CTX.sup.Calc] prophage in addition to the [CTX.sup.ET] prophage. As a result of heteroimmunity, toxigenic classical strains of V. cholerae O1 are known to be infected by CTXF isolated from El Tor biotype strains; toxigenic El Tor strains are resistant to further infection by the same phage. Similarly, strains carrying an El Tor type CTX prophage can be superinfected by the Calcutta type CTX phage (29). Therefore, the new epidemic strains appear to have arisen by acquisition of a Calcutta type CTX phage by strains that originally harbored only El Tor type CTX prophage, since the new strains carry both prophages (Figure 3). What determines the reemergence of particular epidemic strains is not clear, but this study clearly shows changes in the CTX genotype attributed to the acquisition of a new CTX phage by the O139 strains associated with the recent epidemic.

[FIGURE 3 OMITTED]

Antibiogram of Reemergent O139 Strains

V cholerae O139, which emerged during 1992 and 1993, was sensitive to tetracycline and showed a trend of increased resistance to trimethoprim-sulfamethoxazole (SXT) and streptomycin. This resistance was mediated by a ~99-kb self-transmissible transposon-like element (SXT constin) encoding resistance to sulfamethoxazole, trimethoprim, and streptomycin, the resistance genes being clustered together in a 9.4-kb region (19). In the present study, all strains isolated from the recent epidemic were found to be susceptible to SXT and streptomycin (Table). To identify the genetic changes associated with the observed SXT sensitivity, we used a cloned SXT gene probe to study restriction fragment length polymorphism in the SXT transposon. Three different BglI restriction patterns (patterns A-C) of the SXT element were observed among the O139 strains tested (Figure 4). Strains producing pattern A and B were resistant to SXT and streptomycin and included strains isolated between 1992 and 1996, whereas all strains from the recent epidemic produced pattern C and were susceptible to all the three antibiotics. Further analysis of the restriction patterns suggests that the restriction site heterogeneity possibly occurred as a result of a deletion of approximately a 3.6-kb region of the SXT element in strains that were sensitive to SXT and streptomycin. The deletion in the SXT element associated with sensitivity to SXT and streptomycin was first detected in strains of ribotype B-III isolated from an outbreak in Bangladesh in 1997 (6). In keeping with the observation in Bangladesh, comparison of the antibiotic resistance patterns between the O139 strains isolated during 1992 and 1993 and those isolated in 1996 and 1997 in India also showed that the later strains were susceptible to SXT, unlike the O139 strains from 1992 and 1993 (30). However, in contrast to the previously isolated O139 strains, all O139 strains isolated from the recent epidemic were resistant to nalidixic acid.

[FIGURE 4 OMITTED]

Epidemiologic Importance of Genetic Changes in V. cholerae O139

Several previous studies have shown that the O139 serogroup of V. cholerae has been undergoing rapid genetic changes (6-8) since its first emergence. We speculate that the observed changes may have provided increased fitness to strains of this serogroup in some unexplained way to survive in competition with the existing seventh pandemic strain of V cholerae O1 and establish itself as the etiologic agent of a possible eighth pandemic. The transient disappearance of the O139 serogroup in Bangladesh and repeated reemergence associated with somewhat altered genetic or phenotypic properties seem to support this speculation. Our study demonstrated the reemergence of V. cholerae O139 strains belonging to a previously described ribotype which has sustained at least three major genetic and phenotypic changes. These changes include the acquisition of a new CTX prophage, deletion in the SXT element associated with reversion of drug resistance phenotype against SXT and streptomycin, and development of nalidixic acid resistance.

The recent epidemic strains were otherwise similar to previously described O139 strains, including possession of the TCP pathogenicity island, as evidenced by the presence of tcpA, tcpI, and acfB genes; the virulence regulatory genes, toxT and toxR; and the O139-serotype-specific DNA. The role of environmental and host factors that contribute to the emergence of new strains associated with epidemic outbreaks is not clearly known. In the present study, all strains isolated from the recent cholera outbreak belonged to the same ribotype and were genetically and phenotypically identical, suggesting that the recent outbreak in Bangladesh probably started from a point source and may have coincided with the acquisition of one or more critical new properties by a previously existing V cholerae O139 strain. Clearly these properties included the acquisition of the Calcutta Type CTX prophage. Previous studies showed that O139 strains prevailing in Calcutta during 1996 carried this prophage (29,31,32), which might have contributed to the dissimilar incidence of O139 cholera in Calcutta and Dhaka during that period (33). How the initial enrichment oh V cholerae occurred before the initiation of an epidemic is not clear. We speculate that a critical factor for the recent reemergence of O139 vibrios might have been the development of nalidixc acid resistance. Identifying the first index case of the present cholera epidemic is not possible. A spontaneous nalidixic acid-resistant V. cholerae O139 strain may have been enriched in a patient undergoing nalidixc acid therapy, leading to the eventual spread of the organists. This is certainly possible in view of the widespread use of nalidixic acid in Bangladesh as a drug to treat other gastroenteritis, including shigellosis. The emergence of Y: cholerae O139 has received global attention not only as the first non-O1 V. cholerae capable of causing epidemic outbreaks but also because of the rapid genetic re-assortment undergone by strains of this new serogroup. Our study shows yet another set of genetic and phenotypic changes in O139 vibrios and their association with an epidemic of cholera in Bangladesh. These results emphasize the need for continuing molecular epidemiologic surveillance of V. cholerae in Bangladesh and adjoining areas.

Table. Comparative analysis of 63 Vibrio cholerae O139
strains isolated from a recent epidemic in Bangladesh
versus O139 strains isolated between 1993 and 1998
in different countries

Y of                      No. of     Ribo-
isolation    Country     isolates   type (a)

1993        Bangladesh      5         B-I
1993        Bangladesh      1         B-II
1993-1995   Bangladesh      5         B-II
1997        Bangladesh      3         B-II
1997        Bangladesh      3         B-III
1992          India         3         B-I
1993          India         1         B-V
1994          India         1         B-IV
1996          India         2         B-II
1998         Thailand       2         B-I
2002        Bangladesh      63        B-II

                                Presence of genes (b)

Y of                     rst[R.     rst[R.      rst[R.
isolation    Country     sup.ET]   sup.Clas]   sup.Cal]   rstC

1993        Bangladesh      +          -          -        +
1993        Bangladesh      +          -          -        +
1993-1995   Bangladesh      +          -          -        +
1997        Bangladesh      +          -          -        +
1997        Bangladesh      +          -          -        +
1992          India         +          -          -        +
1993          India         +          -          -        +
1994          India         +          -          -        +
1996          India         +          -          -        +
1998         Thailand       +          -          -        +
2002        Bangladesh      +          -          +        +

Y of                         STX
isolation    Country     genotype (a)       Antibiogram (c)

1993        Bangladesh        A         [S.sup.R], SX[T.sup.R]
1993        Bangladesh        B         [S.sup.R], SX[T.sup.R]
1993-1995   Bangladesh        A         [S.sup.R], SX[T.sup.R]
1997        Bangladesh        C             Susceptible (b)
1997        Bangladesh        C             Susceptible (b)
1992          India           A         [S.sup.R], SX[T.sup.R]
1993          India           A         [A.sup.R], [S.sup.R],
                                             SX[T.sup.R]
1994          India           A         [S.sup.R], SX[T.sup.R]
1996          India           A         [A.sup.R], [Fz.sup.R],
                                        [S.sup.R], SX[T.sup.R]
1998         Thailand         A         [S.sup.R], SX[T.sup.R]
2002        Bangladesh        C              [Nal.sup.R]

(a) Ribotypes and SXT genotypes are based on Bg/I
restriction patterns of the respective genes and their
flanking chromosomal sequence.

(b) All strains were positive for tcpA, tcpI, acfB, toxT,
ctxA, zot, and ToxR genes as well as for the O139-specific
genomic DNA in DNA probe or polymerase chain reaction assays.

(c) All strains were susceptible to tetracycline, ampicillin,
chloramphenicol, gentamicin, ciprofloxacin, norfloxacin,
nalidixic acid, streptomycin, trimethoprim, and sulfamethoxazole.

Acknowledgments

We thank Matthew Waldor for the SXT and rstR gene probes and Afjal Hossain for secretarial assistance.

This research was funded by the Swedish International Development Agency (SIDA) under an agreement with the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) and USAID-Washington grant number HRN-A-00-96-90005-00. The ICDDR,B is supported by countries and agencies that share its concern for the health problems of developing countries. Current donors providing unrestricted support include the aid agencies of the governments of Australia, Bangladesh, Belgium, Canada, Japan, Kingdom of Saudi Arabia, the Netherlands. Sweden, Sri Lanka, Switzerland, and the United States.

References

(1.) Cholera Working Group, International Centre of Diarrhoeal Disease Research, Bangladesh. Large epidemic of cholera like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 1993;342:387-90.

(2.) Ramamurthy T. Garg S, Sharma R, Bhattacharya SK, Nair GB, Shimada T, et al. Emergence of a novel strain of Vibrio cholerae with epidemic potential in Southern and Eastern India. Lancet 1993;341:703-4.

(3.) Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics and ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev 1998;62:1301-14.

(4.) Faruque ASG, Fuchs CA, Albert MJ. Changing epidemiology of cholera due to Vibrio cholerae O1 and O139 Bengal in Dhaka, Bangladesh. Epidemiol Infect 1996;116:275-8.

(5.) Faruque SM, Ahmed KM, Alim ARMA, Qadri F, Siddique AK, Albert MJ. Emergence of a new clone of toxigenic Vibrio cholerae biotype El Tor displacing V. cholerae O139 Bengal in Bangladesh. J Clin Microbiol 1997;35:624-30.

(6.) Faruque SM, Siddique AK, Saha MN, Asadulghani, Rahman MM, Zaman K, et al. Molecular characterization of a new ribotype of Vibrio cholerae O139 Bengal associated with an outbreak of cholera in Bangladesh. J Clin Microbiol 1999;37:1313-8.

(7.) Faruque SM, Saha MN, Asadulghani, Bag PK, Bhadra PK. Bhattacharya SK,et al. Genomic diversity among Vibrio cholerae O139 strains isolated in Bangladesh and India between 1992 and 1998. FEMS Microbiol Lett 2000;184:279-84.

(8.) Faruque SM, Saha MN, Asadulghani, Sack DA, Sack RB, Takeda Y, et al. The O139 serogroup of Vibrio cholerae comprises diverse clones of epidemic and nonepidemic strains derived from multiple V. cholerae O1 and non-O1 progenitors. J Infect Dis 2000;182:1161-8.

(9.) World Health Organization. World Health Organization guidelines for the laboratory diagnosis of cholera. Geneva: The Organization; 1974.

(10.) Keasler SP, Hall RH. Detection and biotyping Vibrio cholerae O1 with multiplex polymerase chain reaction. Lancet 1993;341:1661.

(11.) Faruque SM, Asadulghani, Kamruzzaman M, Nandi RK, Ghosh AN, Nair GB, et al. RS1 element of Vibrio cholerae can propagate horizontally as a filamentous phage exploiting the morphogenesis genes of CTXF. Infect Immun 2002;70:163-70.

(12.) Kaper JB, Morris JG Jr, Nishibuchi M. DNA probes for pathogenic Vibrio species. In: Tenover FC, editor. DNA probes for infectious disease. Boca Raton (FL): CRC Press, Inc.; 1988. p. 65-77.

(13.) Faruque SM, Asadulghani, Saha MN, Alim ARMA, Albert MJ, Islam KMN, et al. Analysis of clinical and environmental strains of nonloxigenic Vibrio cholerae for susceptibility to CTXF: molecular basis for the origination of new strains with epidemic potential. Infect Immun 1998;66:5819-25.

(14.) Miller VL, Mekalanos JJ. Synthesis of cholera toxin is positively regulated at the transcriptional level by toxR. Proc Natl Acad Sci U S A 1984;81:3471-5.

(15.) Kimsey HH, Waldor MK. CTXF immunity: application in the development of cholera vaccines. Proc Natl Acad Sci U S A 1998;95:7035-9.

(16.) Brosius J, Ullrich A, Raker MA, Gray A, Dull TJ, Gutell RR, et al. Construction and fine mapping of recombinant plasmids containing the rrnB ribosomal RNA operon of E. coli. Plasmid 1981;6:112-8.

(17.) Nair GB, Bag PK, Shimada T, Ramamurthy T, Takeda T. Yamamoto S, et al. Evaluation of DNA probes for specific detection of Vibrio cholerae O139 Bengal. J Clin Microbiol 1995;33:2186-7.

(18.) Waldor MK, Mekalanos JJ. Vibrio cholerae O139 specific gene sequence. Lancet 1994;343:1366.

(19.) Hochhut B, Lotfi Y, Mazel D, Faruque SM, Woodgate R, Waldor MK. Molecular analysis of antibiotic resistance gene clusters in Vibrio cholerae O139 and O1 SXT constins. Antimicrob Agents Chemother 2002;45:2991-3000.

(20.) Stull TL, LiPuma JJ, Edlind TD. A broad spectrum probe for molecular epidemiology of bacteria: ribosomal RNA. J Infect Dis 1988;157:280-6.

(21.) Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory; 1982.

(22.) Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975;98:503-17.

(23.) Feinberg A. Volgelstein B. A technique for radio labelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1984;137266-7.

(24.) Bauer AW, Kirby WMM, Sherris JC, Turk M. Antibiotic susceptibility by a standardized single disk method. Am J Clin Pathol 1966;45:493-6.

(25.) Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 1996;272:1910-4.

(26.) Waldor MK, Rubin EJ, Gregory DN, Kimsey HH, Makalanos JJ. Regulation, replication and integration functions of the Vibrio cholerae CTXF are encoded by region RS2. Mol Microbiol 1997;24:917-26.

(27.) Boyd EF, Heilpern AJ, Waldor MK. Molecular analysis of a putative CTXF precursor and evidence for independent acquisition of distinct CTXFs by toxigenic Vibrio cholerae. J Bacteriol 2000;182:5530-8.

(28.) Davis BM, Moyer KE, Boyd EF, Waldor MK. CTX prophages in classical biotype of Vibrio cholera: functional phage genes but dysfunctional phage genomes. J Bacteriol 2000;182:6992-8.

(29.) Davis BM, Kimsey HH, Chang W, Waldor MK. The Vibrio cholerae O139 Calcutta bacteriophage. CTXF is infectious and encodes a novel repressor. J Bacteriol 1999;181:6779-87.

(30.) Mitra R, Basu A, Dutta D, Nair GB, Takeda Y. Resurgence of Vibrio cholera,, O139 Bengal with altered antibiogram in Calcutta, India. Lancet 1996;348:1181.

(31.) Sharma C, Maiti S, Mukhopadhyay AK, Basu A, Nair GB, Mukhopadhyaya R, et al. Unique organization of the CTX genetic element in Vibrio cholera O139 strains which reemerged in Calcutta, India, in September, 1996. J Clin Microbiol 1997;35:3348-50.

(32.) Kimsey HH, Nair GB, Ghosh A, Waldor MK. Diverse CTXF and evolution of new pathogenic Vibrio cholera. Lancet 1998;352:457-8.

(33.) Basu A, Mukhopadhyay AK, Sharma C, Jyot J, Gupta N, Ghosh A, et al. Heterogeneity in the organization of the CTX genetic element in strains of Vibrio cholerae O139 Bengal isolated from Calcutta, India and Dhaka, Bangladesh and its possible link to the dissimilar incidence of O139 cholera in the two locales. Microb Pathog 1998;24:175-83.

Dr. Faruque is a scientist at the International Centre for Diarrheal Disease Research, Bangladesh and the head of the Molecular Genetics Unit. His major research interests include microbial evolution, epidemiology and prevention of cholera, and environmental microbiology. Dr. Faruque's current work focuses on understanding the molecular basis for the emergence of epidemic V. cholerae strains and developing vaccines against cholera.

Address for correspondence: David A. Sack, Director, ICDDR,B, GPO Box 128, Dhaka-1000, Bangladesh; fax: [phone]; email: [e-mail]

Shah M. Faruque, * Nityananda Chowdhury, * M. Kamruzzaman, * Q. Shafi Ahmad, * A.S.G. Faruque, * M. Abdus Salam, * T. Ramamurthy, ([dagger]) G. Balakrish Nair, * Andrej Weintraub, ([double dagger]) and David A. Sack *

* International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh, ([dagger]) National Institute of Cholera and Enteric Diseases, Beliaghata, Calcutta, India, and ([double dagger]) Karolinska Instute, Huddinge, Sweden